You are here
Profiles and Perspectives
Stem Cells Trans Med 2014; 3:1253-1258; first published on October 30, 2014; doi:10.5966/sctm.2014-0191
The goal of exploiting induced pluripotent stem cell (iPSC) technology for the discovery of new mechanisms and treatments of disease is being pursued by many laboratories, and analyses of rare monogenic diseases have already provided ample evidence that this approach has merit.
Stem Cells Trans Med 2014; 3:1259-1261; first published on September 17, 2014; doi:10.5966/sctm.2014-0125
Many clinical trials of stem cell therapy over the last decade have included small study groups, limiting their scientific value and rendering their ethical justification questionable. Open-source clinical development might enhance transparency of results from stem cell research, improve data on safety outcomes, and minimize overestimation of effects caused by publication bias, which will advance progress in stem cell therapy and provide opportunities for generalizing study results.
Stem Cells Trans Med 2014; 3:1262-1268; first published on September 17, 2014; doi:10.5966/sctm.2014-0086
Glioblastoma (GBM) is a primary brain cancer with an extremely poor prognosis. Recent studies in Drosophila and mammalian models (e.g., xenografts of human cancer cells into small animals) are summarized to elucidate the intercellular interactions between apoptosis-prone cancer cells and hyperproliferative cancer cells.
Stem Cells Trans Med 2014; 0:sctm.2014-0147v1-sctm.2014-0147; first published on October 8, 2014; doi:10.5966/sctm.2014-0147
This study examines the major ethical and social questions raised by the cancellation of the 2010 phase I clinical trial of a human embryonic stem cell-based therapy for spinal cord injury. The study provides recommendations for institutional review boards and clinical sites as they deliberate approvals of early-phase trials in frontier medicine.
Stem Cells Trans Med 2014; 0:sctm.2014-0085v1-sctm.2014-0085; first published on August 13, 2014; doi:10.5966/sctm.2014-0085
Recent exciting but limited evidence supports the intriguing concept of genetic and phenotypic diversity in the cancer stem cell (CSC) population. The authors of this paper consider whether CSC heterogeneity at the inter- and intrapatient levels may be due to the cell of origin, to environmental cues, and/or to human papillomavirus infection.
Ellen G. Feigal, Katherine Tsokas, Sowmya Viswanathan, Jiwen Zhang, Catherine Priest, Jonathan Pearce, and Natalie Mount
Stem Cells Trans Med 2014; 3:879-887; doi:10.5966/sctm.2014-0122
The International Workshop on Regulatory Pathways for Cell Therapies was convened in September 2013 to discuss the nature of regenerative medicine as a rapidly evolving field with novel scientific and regulatory challenges and to highlight opportunities for potential convergence between different regulatory bodies that might assist the field’s development.
Stem Cells Trans Med 2014; 3:782-786; first published on May 15, 2014; doi:10.5966/sctm.2014-0013
Stem Cells Trans Med 2014; 3:673-674; first published on April 25, 2014; doi:10.5966/sctm.2014-0069
Stem Cells Trans Med 2014; 3:549-552; first published on March 19, 2014; doi:10.5966/sctm.2013-0205
Stem Cells Trans Med 2014; 3:553-559; first published on April 1, 2014; doi:10.5966/sctm.2013-0194
The array of human pluripotent stem cells now includes embryonic stem cells, induced pluripotent stem cells, and amniotic fluid stem cells. This article compares several aspects of these stem cell types and highlights the need for future appropriate methodological management to include a decision on the “optimal” stem cell to use for a specific application.